◆英語タイトル:Crescendo Biologics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014062
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company s pipeline includes humabody programs targeting oncology. It specializes in the antibody discoveries and development that include CAT, medimmune, morphosys and GSK. Crescendo develops a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The company’s oncology programmes produce high value, novel therapeutics that capitalizes on advantages of the Humabody VH format. Crescendo is headquartered in Cambridge, the UK.
Crescendo Biologics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 10
Crescendo Biologics Raises US$3.3 Million In Series A Financing 11
Crescendo Biologics Raises US$28 Million In Series A Financing 12
Licensing Agreements 14
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 14
Crescendo Biologics Ltd – Key Competitors 15
Crescendo Biologics Ltd – Key Employees 16
Crescendo Biologics Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jun 14, 2017: Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer 18
Apr 03, 2017: Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer 19
Oct 18, 2016: Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer 20
Product News 21
02/08/2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22
List of Tables
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescendo Biologics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescendo Biologics Raises Funds through Venture Financing 10
Crescendo Biologics Raises US$3.3 Million In Series A Financing 11
Crescendo Biologics Raises US$28 Million In Series A Financing 12
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 14
Crescendo Biologics Ltd, Key Competitors 15
Crescendo Biologics Ltd, Key Employees 16